The Personal Antipsychotic Choice Index

Abstract

Introduction We present an online decision aid to involve patients with a psychotic disorder in shared decision-making concerning the selection of antipsychotic medication.

Method Patients selected effectiveness and adverse effects criteria from the Subject’s Response to Antipsychotics-34 questionnaire. Numerical data from meta-analyses, clinical trial data, receptor affinities and expert opinions were used to rank antipsychotics on each criterion. When using the the tool, patients indicate on a 5-point Likert scale how they value each (adverse) effect. The Likert scale values are combined in an algorithm with the rank orders of antipsychotics to create a personalized ranking.

Results Criteria used were: effectiveness concerning psychotic, depressive and cognitive symptoms, weight gain, sexual dysfunction, drowsiness, hypersomnia, extrapyramidal symptoms, anticholinergic adverse effects, hypersalivation, nausea, dizziness, energy loss, blunted affect/less need for companionship. High-level evidence was available for ranking weight gain, sexual dysfunction, menstrual disorders, extrapyramidal symptoms and effectiveness on psychotic symptoms. We used lower level evidence ranking the remaining criteria.

Discussion A transparent procedure has resulted in an updateable tool to produce individual ranking of antipsychotics based on the patients’ input.

Key words

antipsychotics - psychosis - shared decision making - adherence - web tool

• References

• 1 Lambert M, Conus P, Cotton S. et al. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol. 2010; 30: 565-572
• 2 Barkhof E, Meijer CJ, de Sonneville LMJ. et al. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–a review of the past decade. Eur Psychiatry. 2012; 27: 9-18
• 3 Heeg B, Buskens E, Knapp M. et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 (Suppl. 01) 17-33
• 4 Day JC, Bentall RP, Roberts C. et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005; 62: 717-724
• 5 Hamann J, Coden R, Leucht S. et al. Do patients with schizophrenia wish to be involved in decisions about their medical treatment?. Am J Psychiatry 2005; 162: 2382-2384
• 6 De Haan L, Van Raaij B, Van Den Berg R. et al. Preferences for treatment during a first psychotic episode. Eur Psychiatry. 2001; 16: 83-89
• 7 De Haan L, Weisfelt M, Dingemans PMAJ. et al. Psychometric properties of the subjective well-being under neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 2002; 162: 24-28
• 8 O’Connor AM, Bennett CL, Stacey D. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009; 8: CD001431
• 9 Armando J, Rotondi PD, Carol M. et al. Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes. Psychiatr Serv. 2010; 61: 1099-1105
• 10 van der Krieke L, Emerencia AC, Boonstra N. et al. A web-based tool to support shared decision making for people with a psychotic disorder: randomized controlled trial and process evaluation. J Med Internet Res. 2013; 15: e216
• 11 Rotondi AJ, Eack SM, Hanusa BH. et al. Critical design elements of e-health applications for users with severe mental illness: singular focus, simple architecture, prominent contents, explicit navigation, and inclusive hyperlinks. Schizophr Bull. 2015; 41: 440-448
• 12 Lako IM, Bruggeman R, Liemburg EJ. et al. A brief version of the Subjects’ Response to Antipsychotics questionnaire to evaluate treatment effects. Schizophr Res. 2013; 147: 175-180
• 13 Leucht S, Winter-van Rossum I, Heres S. et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015; 41: 549-558
• 14 Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion. Drugs 1997; 53: 550-562
• 15 Lader MH. Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiatry. 1993; 54: 493-500
• 16 Leucht S, Cipriani A, Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 17 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
• 18 De Las Cuevas C, Peñate W, de Rivera L. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?. Patient Prefer Adherence 2014; 8: 1547-1553
• 19 Bak M, Fransen A, Janssen J. et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9: e94112
• 20 Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010; 81: 617-622
• 21 Strassnig M, Miewald J, Keshavan M. et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007; 93: 90-98
• 22 Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2005; 4: CD005474
• 23 Mothi M, Sampson S. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev. 2013; 11: CD001949
• 24 Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf 2010; 2: 205-211
• 25 Peuskens J, Pani L, Detraux J. et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28: 421-453
• 26 Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-1711
• 27 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs 2007; 21: 911-936
• 28 Leucht S. Supplementary appendix. Lancet. 2013; 6736:
• 29 Soares BGO, Lima MS. Penfluridol for schizophrenia. Cochrane Database Syst Rev. 2006; 2: CD002923
• 30 Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014; 4: CD007811
• 31 MedicaWiki. MedicaWiki. Available from: http://medicawiki.eu/wiki/Main_Page Accessed on: September 1, 2012
• 32 Schillevoort I, de Boer A, Herings RMC. et al. Antipsychotic-induced extrapyramidal syndromes. Eur J Clin Pharmacol. 2001; 57: 327-331
• 33 Chew ML, Mulsant BH, Pollock BG. et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res. 2006; 88: 63-72
• 34 Ishibashi T, Horisawa T, Tokuda K. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334: 171-181
• 35 Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009; 29: 141-146
• 36 Khanna P, Suo T, Komossa K. et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD006569
• 37 Tuunainen A. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000; 2: CD000966
• 38 Duggan L, Fenton M, Rathbone J. et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; 2: CD001359
• 39 Lataster J, van Os J, de Haan L. et al. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J. Clin Psychiatry. 2011; 72: 1397-1404
• 40 Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998; 3: 123-134
• 41 Revickil DA, Genduso LA, Hamilton SH. et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999; 8: 417-426
• 42 Shen X, Xia J, Adams CE. Flupenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2012; 11: CD009777
• 43 Désaméricq G, Schurhoff F, Meary A. et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014; 70: 127-134
• 44 Farmacotherapeutisch Kompas. Zorginstituut Nederland. Available from: https://www.farmacotherapeutischkompas.nl Accessed on: August 13, 2014
• 45 Alper K, Schwartz KA, Kolts RL. et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007; 62: 345-354
• 46 Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010; 19: 69-73
• 47 Lertxundi U, Hernandez R, Medrano J. et al. Antipsychotics and seizures: higher risk with atypicals?. Seizure 2013; 22: 141-13